San Diego, CA, United States

Prometheus Laboratories

www.prometheuslabs.com
San Diego, CA, United States

Time filter

Source Type

News Article | May 8, 2017
Site: www.prnewswire.com

Laurie Brlas, Perrigo's Chairman, commented, "The additions of Adriana and Rolf to the Perrigo Board further enable us to enhance shareholder value. Their experiences and industry expertise add relevant perspectives as we continue to deliver on our strategic initiatives. On behalf of the Perrigo Board and management team, I want to thank Ellen for her dedication to Perrigo and its shareholders throughout her service." Jeffrey Smith, Starboard's CEO and Chief Investment Officer, said, "Together, the Board and management team continue to make progress on a number of key initiatives. Adriana and Rolf add valuable expertise to this newly constituted Board, which continues to focus on increasing shareholder value." Rolf A. Classon has extensive experience as a senior executive and Board member of a number of international medical device, biotechnology and pharmaceutical companies. He currently serves as Chairman of the Board of Directors at Tecan Group Ltd. and is on the Boards of Catalent, Inc., Fresenius Medical Care AG and Co. and Hill-Rom Holdings, Inc. Mr. Classon has served on a number of other Boards, including Auxilium Pharmaceuticals, Millipore Corporation, and Prometheus Laboratories Inc. He was Chairman of the Executive Committee and CEO for Bayer Healthcare from 2002 to 2004, in addition to holding a number of different positions at Bayer AG between 1991 and 2002. From 2005 to 2006 he served as interim President and CEO at Hillenbrand Industries, and prior to 1991 he held a number of different management positions at Pharmacia Corporation. Rolf will join Perrigo's Nominating and Governance Committee. Adriana Karaboutis currently serves as an independent director on several company Boards including Advance Auto Parts, Inc. and Blue Cross Blue Shield of Massachusetts. Previously, Adriana served as the Executive Vice President, Technology and Business Solutions at Biogen, Inc., where she oversaw information technology and led the digital health technology and advanced analytics team. Prior to her time at Biogen, Ms. Karaboutis was Vice President and Global Chief Information Officer of Dell, Inc., and spent over 20 years at General Motors and Ford Company in various international leadership positions. Adriana will join Perrigo's Audit Committee. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world's largest manufacturer of over-the-counter ("OTC") healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of "extended topical" prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including the time, effort and expense to complete the restatement of its financial statements, future impairment charges, the ability to achieve its guidance, the completion of announced acquisitions or dispositions, the ability to execute and achieve the desired benefits of announced initiatives, and the timing, amount and cost of any share repurchases. In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting, may encounter unanticipated material issues or additional adjustments that could delay the completion of the restatement of its financial statements or the filing of required periodic reports with the SEC, or may be unable to regain compliance with the NYSE continued listing rules. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of the restatement of the Company's financial statements or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-KT for the six-month period ended December 31, 2015, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/perrigo-announces-two-new-independent-directors-300453069.html


Receive press releases from iHealthcareAnalyst, Inc.: By Email Non-Alcoholic Steatohepatitis Biomarkers Market by Biomarkers, End Users, Trends and Forecast to 2021, Upcoming Research by iHealthcareAnalyst, Inc. Non-alcoholic Steatohepatitis Biomarkers Market by Biomarker Type (Apoptosis Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Serum Biomarkers) and End User (Academics and Research Institute, Diagnostic Laboratories, Pharma and CROs, and Hospitals) and Forecast 2017-2021. Maryland Heights, MO, May 06, 2017 --( Visit Non-alcoholic Steatohepatitis Biomarkers Market by Biomarker Type (Apoptosis Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Serum Biomarkers) and End User (Academics and Research Institute, Diagnostic Laboratories, Pharma and CROs, and Hospitals) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/non-alcoholic-steatohepatitis-biomarkers-market/. The global non-alcoholic steatohepatitis biomarkers market segmentation is based on biomarker type (apoptosis biomarkers, hepatic fibrosis biomarkers, oxidative stress biomarkers, serum biomarkers) and end user (academics and research institute, diagnostic laboratories, pharma and CROs, and hospitals). The global non-alcoholic steatohepatitis biomarkers market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global non-alcoholic steatohepatitis biomarkers market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global non-alcoholic steatohepatitis biomarkers market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market. Major players operating in the global non-alcoholic steatohepatitis biomarkers market and included in this report are BioPredictive S.A.S, Exalenz Biosciences Ltd., Genfit SA, One Way Liver S.L., Prometheus Laboratories Inc. (Nestle Health Sciences), Quest Diagnostics Incorporated, Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics), and Siemens Healthcare Private Ltd. (Siemens Healthineers). 1. Biomarker Type 1.1. Apoptosis Biomarkers 1.2. Hepatic Fibrosis Biomarkers 1.3. Oxidative Stress Biomarkers 1.4. Serum Biomarkers 1.5. Others 2. End User 2.1. Academics and Research Institutes 2.2. Diagnostic Laboratories 2.3. Hospitals 2.4. Pharma and CROs 3. Geography 3.1. North America (U.S., Canada) 3.2. Latin America (Brazil, Mexico, Rest of LA) 3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 3.4. Asia Pacific (Japan, China, India, Rest of APAC) 3.5. Rest of the World 4. Company Profile 4.1. BioPredictive S.A.S 4.2. Exalenz Biosciences Ltd. 4.3. Genfit SA 4.4. One Way Liver S.L. 4.5. Prometheus Laboratories Inc. (Nestle Health Sciences) 4.6. Quest Diagnostics Incorporated 4.7. Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics) 4.8. Siemens Healthcare Private Ltd. (Siemens Healthineers) To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/non-alcoholic-steatohepatitis-biomarkers-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, May 06, 2017 --( PR.com )-- Non-alcoholic Steatohepatitis or Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic steatohepatitis (NASH) and irreversible liver damage (cirrhosis). Biomarkers offer a potential prognostic or diagnostic indicator for disease manifestation, progression or both. Serum biomarkers, including total cholesterol, triglycerides, insulin resistance and C-peptide, have been used for many years. Emerging biomarkers, such as apolipoprotein A1, apolipoprotein B, leptin, adiponectin, free fatty acids, ghrelin and tumour necrosis factor-alpha, have been proposed as tools that could provide valuable complementary information to that obtained from traditional biomarkers. Moreover, markers of cell death and mitochondrial dysfunction (cytokeratins) represent powerful predictors of risk. For biomarkers to be clinically useful in accurately diagnosing and treating disorders, age-specific reference intervals that account for differences in sex and ethnic origin are a necessity.Visit Non-alcoholic Steatohepatitis Biomarkers Market by Biomarker Type (Apoptosis Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Serum Biomarkers) and End User (Academics and Research Institute, Diagnostic Laboratories, Pharma and CROs, and Hospitals) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/non-alcoholic-steatohepatitis-biomarkers-market/.The global non-alcoholic steatohepatitis biomarkers market segmentation is based on biomarker type (apoptosis biomarkers, hepatic fibrosis biomarkers, oxidative stress biomarkers, serum biomarkers) and end user (academics and research institute, diagnostic laboratories, pharma and CROs, and hospitals).The global non-alcoholic steatohepatitis biomarkers market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global non-alcoholic steatohepatitis biomarkers market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global non-alcoholic steatohepatitis biomarkers market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.Major players operating in the global non-alcoholic steatohepatitis biomarkers market and included in this report are BioPredictive S.A.S, Exalenz Biosciences Ltd., Genfit SA, One Way Liver S.L., Prometheus Laboratories Inc. (Nestle Health Sciences), Quest Diagnostics Incorporated, Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics), and Siemens Healthcare Private Ltd. (Siemens Healthineers).1. Biomarker Type1.1. Apoptosis Biomarkers1.2. Hepatic Fibrosis Biomarkers1.3. Oxidative Stress Biomarkers1.4. Serum Biomarkers1.5. Others2. End User2.1. Academics and Research Institutes2.2. Diagnostic Laboratories2.3. Hospitals2.4. Pharma and CROs3. Geography3.1. North America (U.S., Canada)3.2. Latin America (Brazil, Mexico, Rest of LA)3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)3.4. Asia Pacific (Japan, China, India, Rest of APAC)3.5. Rest of the World4. Company Profile4.1. BioPredictive S.A.S4.2. Exalenz Biosciences Ltd.4.3. Genfit SA4.4. One Way Liver S.L.4.5. Prometheus Laboratories Inc. (Nestle Health Sciences)4.6. Quest Diagnostics Incorporated4.7. Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics)4.8. Siemens Healthcare Private Ltd. (Siemens Healthineers)To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/non-alcoholic-steatohepatitis-biomarkers-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill DriveMaryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


Patent
Prometheus Laboratories | Date: 2012-04-06

The present invention provides assays for detecting and measuring the presence or level of anti-TNF drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.


Patent
Prometheus Laboratories | Date: 2012-02-03

The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy.


Patent
Prometheus Laboratories | Date: 2012-04-06

The invention provides novel biomarkers, kits, and methods of diagnosing, prognosing, and subtyping IBS. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of novel IBS biomarkers identified herein.


The present invention provides methods for selecting a suitable anticancer therapy and for identifying and predicting response for the treatment of a gastric cancer by determining the expression level and/or activation level of one or more analytes in a cell such as a cancer cell from an ascites sample. The present invention also provides methods for selecting a suitable anticancer therapy and for identifying and predicting response for the treatment of a lung cancer such as a non-small cell lung cancer by determining the expression level and/or activation level of one or more analytes in a cell such as a cancer cell from a pleural efflux sample.


Patent
Prometheus Laboratories | Date: 2012-01-17

The invention provides an ELISA assay for the determination of serum mast cell -tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of -tryptase, histamine and/or prostaglandin E_(2).


Patent
Prometheus Laboratories | Date: 2012-12-10

The present invention provides methods for analyzing genetic and/or metabolite biomarkers to individualize methotrexate (MTX) therapy. For example, the assay methods of the present invention are useful for predicting whether a patient will respond to MTX and/or has a risk of developing toxicity to MTX based upon the genotype of one or more folate pathway genes. The assay methods of the present invention are also useful for optimizing the dose of MTX in a patient already receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects based upon the genotype of one or more folate pathway genes. In addition, the assay methods of the present invention are useful for predicting or optimizing the therapeutic response to MTX in a patient based upon the methotrexate polyglutamate and/or folate polyglutamate levels in a sample from the patient.


Patent
Prometheus Laboratories | Date: 2012-04-04

The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.


Patent
Prometheus Laboratories | Date: 2012-01-30

The present invention provides antibody-based arrays for detecting the activation state and/or total amount of one or a plurality of oncogenic fusion proteins in a biological sample such as whole blood or tumor tissue and methods of use thereof. In certain instances, the activation state and/or total amount of oncogenic fusion protein(s) present in a sample can be measured in combination with one or a plurality of signal transduction molecules. The compositions and methods of the present invention have the advantages of specificity associated with enzyme-linked immunosorbent assays, sensitivity associated with signal amplification, and high-throughput multiplexing associated with microarrays.

Loading Prometheus Laboratories collaborators
Loading Prometheus Laboratories collaborators